Literature DB >> 33137577

Deciphering the clonal relationship between glandular and squamous components in adenosquamous carcinoma of the lung using whole exome sequencing.

Arthur Krause1, Luca Roma1, Thomas Lorber1, James Habicht2, Didier Lardinois3, Maria Rosaria De Filippo4, Spasenija Savic Prince1, Salvatore Piscuoglio5, CharlotteKY Ng6, Lukas Bubendorf7.   

Abstract

Adenosquamous carcinoma of the lung (ASC) is a rare subtype of non-small cell lung cancer, consisting of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) components. ASC shows morphological characteristics of classic LUAD and LUSC but behaves more aggressively. Although ASC can serve as a model of lung cancer heterogeneity and transdifferentiation, its genomic background remains poorly understood. In this study, we sought to explore the genomic landscape of macrodissected LUAD and LUSC components of three ASC using whole exome sequencing (WES). Identified truncal mutations included the pan-cancer tumor-suppressor gene TP53 but also EGFR, BRAF, and MET, which are characteristic for LUAD but uncommon in LUSC. No truncal mutation of classical LUSC driver mutations were found. Both components showed unique driver mutations that did not overlap between the three ASC. Mutational signatures of truncal mutations differed from those of the branch mutations in their descendants LUAD and LUSC. Most common signatures were related to aging (1, 5) and smoking (4). Truncal chromosomal copy number aberrations shared by all three ASC included losses of 3p, 15q and 19p, and an amplified region in 5p. Furthermore, we detected loss of STK11 and SOX2 amplification in ASC, which has previously been shown to drive transdifferentiation from LUAD to LUSC in preclinical mouse models. Conclusively, this is the first study using WES to elucidate the clonal evolution of ASC. It provides strong evidence that the LUAD and LUSC components of ASC share a common origin and that the LUAD component appears to transform to LUSC.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adenosquamous carcinoma; Genomic evolution; Heterogeneity; Lung cancer; SOX2; STK11

Mesh:

Year:  2020        PMID: 33137577     DOI: 10.1016/j.lungcan.2020.10.013

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  5 in total

1.  Genomic evolutionary trajectory of metastatic squamous cell carcinoma of the lung.

Authors:  Arthur Krause; Luca Roma; Thomas Lorber; Tanja Dietsche; Valeria Perrina; David C Müller; Didier Lardinois; Christian Ruiz; Spasenija Savic Prince; Salvatore Piscuoglio; Charlotte K Y Ng; Lukas Bubendorf
Journal:  Transl Lung Cancer Res       Date:  2021-04

2.  Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma.

Authors:  Lingling Zhu; Yanyang Liu; Honglin Gao; Jiewei Liu; Qinghua Zhou; Feng Luo
Journal:  Front Cell Dev Biol       Date:  2022-01-10

3.  Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation.

Authors:  Charles M Rudin; Alvaro Quintanal-Villalonga; Hirokazu Taniguchi; Yingqian A Zhan; Maysun M Hasan; Shweta S Chavan; Fanli Meng; Fathema Uddin; Viola Allaj; Parvathy Manoj; Nisargbhai S Shah; Joseph M Chan; Metamia Ciampricotti; Andrew Chow; Michael Offin; Jordana Ray-Kirton; Jacklynn D Egger; Umesh K Bhanot; Irina Linkov; Marina Asher; Michael H Roehrl; Katia Ventura; Juan Qiu; Elisa de Stanchina; Jason C Chang; Natasha Rekhtman; Brian Houck-Loomis; Richard P Koche; Helena A Yu; Triparna Sen
Journal:  J Hematol Oncol       Date:  2021-10-16       Impact factor: 17.388

Review 4.  State-of-the-art combination treatment strategies for advanced stage non-small cell lung cancer.

Authors:  Yongfang Yao; Rameesha Fareed; Aliya Zafar; Kalsoom Saleem; Tao Huang; Yongtao Duan; Masood Ur Rehman
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

5.  Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma.

Authors:  Chao Li; Xiaobin Zheng; Pansong Li; Huijuan Wang; Jie Hu; Lin Wu; Zhijie Wang; Hui Guo; Fang Wu; Wenzhao Zhong; Chengzhi Zhou; Qian Chu; Jun Zhao; Xinlong Zheng; Weijin Xiao; Weifeng Zhu; Longfeng Zhang; Qian Li; Kan Jiang; Qian Miao; Biao Wu; Yiquan Xu; Shiwen Wu; Haibo Wang; Shanshan Yang; Yujing Li; Xuefeng Xia; Xin Yi; Cheng Huang; Bo Zhu; Gen Lin
Journal:  Front Immunol       Date:  2022-08-12       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.